NYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis $5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nevro Stock (NYSE:NVRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nevro alerts:Sign Up Key Stats Today's Range$5.84▼$5.8650-Day Range$5.73▼$5.8552-Week Range$3.17▼$11.69Volume753,602 shsAverage Volume756,732 shsMarket Capitalization$224.32 millionP/E RatioN/ADividend YieldN/APrice Target$5.36Consensus RatingReduce Company OverviewNevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Read More… Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Stock News HeadlinesAnalysts Set Nevro Corp. (NYSE:NVRO) PT at $5.36April 25, 2025 | americanbankingnews.comDATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Nevro Corp. Customers Whose Data May Have Been CompromisedApril 10, 2025 | globenewswire.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Nevro Corp. Investigated by Federman & Sherwood for Data BreachApril 3, 2025 | globenewswire.comGlobus Medical Completes Acquisition of Nevro Corp.April 3, 2025 | tipranks.comNevro Corp Completes Merger and Delists from NYSEApril 3, 2025 | tipranks.comGlobus Medical Inc (GMED) Completes Acquisition of Nevro Corp, Expanding Market OpportunitiesApril 3, 2025 | gurufocus.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Globus Medical (GMED) and Vertex Pharmaceuticals (VRTX)March 25, 2025 | markets.businessinsider.comSee More Headlines NVRO Stock Analysis - Frequently Asked Questions How have NVRO shares performed this year? Nevro's stock was trading at $3.72 at the start of the year. Since then, NVRO stock has increased by 57.2% and is now trading at $5.8460. View the best growth stocks for 2025 here. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Tuesday, March, 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.15. The medical equipment provider had revenue of $105.55 million for the quarter, compared to the consensus estimate of $102.61 million. Nevro had a negative trailing twelve-month return on equity of 23.52% and a negative net margin of 16.54%. Who are Nevro's major shareholders? Top institutional shareholders of Nevro include Trium Capital LLP (2.03%), Bank of New York Mellon Corp (0.29%), Rhumbline Advisers (0.15%) and SG Americas Securities LLC (0.14%). Insiders that own company stock include Kashif Rashid and Shawn Mccormick. View institutional ownership trends. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings3/04/2025Today5/03/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NVRO CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,090Year FoundedN/APrice Target and Rating Average Stock Price Target$5.36 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside-8.3%Consensus RatingReduce Rating Score (0-4)1.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-16.54% Pretax Margin-17.89% Return on Equity-23.52% Return on Assets-10.83% Debt Debt-to-Equity Ratio0.67 Current Ratio5.02 Quick Ratio3.76 Sales & Book Value Annual Sales$408.52 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book0.72Miscellaneous Outstanding Shares38,372,000Free Float36,273,000Market Cap$224.32 million OptionableOptionable Beta0.81 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NYSE:NVRO) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.